1 / 11

AIPPI Hyderabad 2011 – Patent Linkage

AIPPI Hyderabad 2011 – Patent Linkage. Patent Linkage - general. Allowing the patent status of an original product to affect regulatory decisions concerning generic products in respect of marketing approval , pricing , reimbursement etc. Patent Linkage - general.

shino
Télécharger la présentation

AIPPI Hyderabad 2011 – Patent Linkage

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. AIPPI Hyderabad 2011– Patent Linkage

  2. Patent Linkage - general • Allowing the patent status of an original productto affectregulatorydecisionsconcerninggenericproducts in respect of marketing approval, pricing, reimbursementetc.

  3. Patent Linkage - general • Starting point for applicable EU regulations that market authorizations shall not be refused, suspended or revoked except on the grounds set out in such regulations. • Article 81 of Regulation (EC) No 726/2004, Article 126 of Directive (EC) No 2001/83 and Recital 3 of Regulation (EEC) 2309/93. • Patent protection is not included as a ground for refusal

  4. Variants of Formal Patent Linkage • Notificationto IP holder of application for marketing approval • Filedeclaration of non-infringement with MA application • Restrictions in respect of earliest date for filingof MA application in relation to lapse of patent • GenericMA suspendeduntillapse of patent rights

  5. ’Indirect’ Patent Linkage • When the actionsnecessary or desirable in order to obtain a relevant regulatorydecisionconcerning a pharmaceuticalproductcan be actionableunder patent laweither as infringementby themselfor consideredproof of imminentinfringementwarrantinginterlocutorymeasures.

  6. Marketing AuthorisationspreBolar • Swedish caselaw to the effect that the paperfilingdid not involveinfringement • Importation of samples for regulatorypurposesinfringed patent rights.

  7. Bolar provision • Directive 2001/83/EC as amended by 2004/27/EC introducedexemptionfrom patent protection in respect of measuresnecessary to obtaingeneric marketing authorisation

  8. Marketing Authorisation • Directivenot directly valid in all EU memberstates and the precise scope of the national legislationimplementing the Directivevaries • Onlygenerics or all pharmaceuticals? • EU/EEA marketing authorisationsonly or a widerscope?

  9. Marketing Authorisation • Portugal – actions before the administrative courts using a specific provision of the Portugueseconstitutionagainstgrant of marketing approval

  10. Price approval/reimbursement • Not infringingaccording to Swedish Supreme Court in Pfizer v Stada (ref NJA 2008 p 1192) • Should it be viewed as an indication of imminentinfringementwarrantinginterimmeasuresaccording to the EnforcementDirective?

  11. Generic substitution • Specific MPA decisionestablishingsubstitutabilitybetween original and genericproduct. • Triggersmandatory substitution at pharmacylevel – switchprescribedpharmaceutical to pharmaceutical with the lowestprice • Risperidal (Janssen-Cilag) - MPA cannotdecide on substitutability for productsprotected by patent and allegingcontributoryinfringement by the MPA – rejected by the court.

More Related